AMRX - רווח נקי למניה (EPS TTM) Amneal Pharmaceuticals, Inc.

Diversification between biosimilars and neurology supports the trend of the 12-month net income per share chart for Amneal Pharmaceuticals (AMRX) on GURU.Markets, where the indicator remains around 0.41. Business efficiency is based on large-scale generic production, which reduces costs. However, geopolitical pressure and a shortage of substances from Asia create risks for the stability of component supplies.
פילוחי נתונים אנליטיים מרוכזים עבור Amneal Corp (AMRX)

Net income per share over 12 months serves as a key barrier of business resilience, measuring the actual income attributable to a single security after all deductions. By analyzing the trailing 12-month earnings per share, an investor can see the results of cost optimization at Amneal Pharmaceuticals (AMRX), where the transition to flexible outsourcing for clinical trials and production directly converts into growth for this fundamental metric.